Abstract

Transient receptor potential canonical (TRPC) proteins form nonselective cation channels that play physiological roles in a wide variety of cells. Despite growing evidence supporting the therapeutic potential of TRPC6 inhibition in treating pathological cardiac and renal conditions, mechanistic understanding of TRPC6 function and modulation remains obscure. Here we report cryo-EM structures of TRPC6 in both antagonist-bound and agonist-bound states. The structures reveal two novel recognition sites for the small-molecule modulators corroborated by mutagenesis data. The antagonist binds to a cytoplasm-facing pocket formed by S1-S4 and the TRP helix, whereas the agonist wedges at the subunit interface between S6 and the pore helix. Conformational changes upon ligand binding illuminate a mechanistic rationale for understanding TRPC6 modulation. Furthermore, structural and mutagenesis analyses suggest several disease-related mutations enhance channel activity by disrupting interfacial interactions. Our results provide principles of drug action that may facilitate future design of small molecules to ameliorate TRPC6-mediated diseases.

Data availability

The low pass filtered and amplitude modified 3D cryo-EM density maps for TRPC6 in complex with antagonist AM-1473 (accession code: EMD-20954) and agonist AM-0883 (accession code: EMD-20953) have been deposited in the electron microscopy data bank. Atomic coordinates for TRPC6 in complex with antagonist AM-1473 (accession code: 6UZA) and agonist AM-0883 (accession code: 6UZ8) have been deposited in the protein data bank.

The following data sets were generated

Article and author information

Author details

  1. Yonghong Bai

    Molecular Engineering, Amgen Inc, Cambridge, United States
    For correspondence
    ybai80@gmail.com
    Competing interests
    Yonghong Bai, At the time of the study YB was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4334-0916
  2. Xinchao Yu

    Molecular Engineering, Amgen Inc, South San Francisco, United States
    For correspondence
    xyu01@amgen.com
    Competing interests
    Xinchao Yu, XY is affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  3. Hao Chen

    Protein Technologies, Amgen Inc, Cambridge, United States
    Competing interests
    Hao Chen, At the time of the study HC was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  4. Daniel Horne

    Medicinal Chemistry, Amgen Inc, Cambridge, United States
    Competing interests
    Daniel Horne, At the time of the study DH was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  5. Ryan White

    Medicinal Chemistry, Amgen Inc, Cambridge, United States
    Competing interests
    Ryan White, At the time of the study RW was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  6. Xiaosu Wu

    Cardiometabolic Disorders, Amgen Inc, South San Francisco, United States
    Competing interests
    Xiaosu Wu, XW is affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  7. Paul Lee

    Discovery Technologies, Amgen Inc, Thousand Oaks, United States
    Competing interests
    Paul Lee, At the time of the study PL was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  8. Yan Gu

    Protein Technologies, Amgen Inc, Cambridge, United States
    Competing interests
    Yan Gu, At the time of the study YG was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  9. Sudipa Ghimire-Rijal

    Molecular Engineering, Amgen Inc, Cambridge, United States
    Competing interests
    Sudipa Ghimire-Rijal, SGR is affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  10. Daniel C-H Lin

    Cardiometabolic Disorders, Amgen Inc, South San Francisco, United States
    For correspondence
    dclin@amgen.com
    Competing interests
    Daniel C-H Lin, DCHL is affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  11. Xin Huang

    Molecular Engineering, Amgen Inc, Cambridge, United States
    For correspondence
    hxin@amgen.com
    Competing interests
    Xin Huang, At the time of the study XH was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..

Funding

No external funding was received for this work.

Copyright

© 2020, Bai et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,019
    views
  • 896
    downloads
  • 79
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yonghong Bai
  2. Xinchao Yu
  3. Hao Chen
  4. Daniel Horne
  5. Ryan White
  6. Xiaosu Wu
  7. Paul Lee
  8. Yan Gu
  9. Sudipa Ghimire-Rijal
  10. Daniel C-H Lin
  11. Xin Huang
(2020)
Structural basis for pharmacological modulation of the TRPC6 channel
eLife 9:e53311.
https://doi.org/10.7554/eLife.53311

Share this article

https://doi.org/10.7554/eLife.53311

Further reading

    1. Structural Biology and Molecular Biophysics
    Yuanyuan Wang, Fan Xu ... Yongning He
    Research Article

    SCARF1 (scavenger receptor class F member 1, SREC-1 or SR-F1) is a type I transmembrane protein that recognizes multiple endogenous and exogenous ligands such as modified low-density lipoproteins (LDLs) and is important for maintaining homeostasis and immunity. But the structural information and the mechanisms of ligand recognition of SCARF1 are largely unavailable. Here, we solve the crystal structures of the N-terminal fragments of human SCARF1, which show that SCARF1 forms homodimers and its epidermal growth factor (EGF)-like domains adopt a long-curved conformation. Then, we examine the interactions of SCARF1 with lipoproteins and are able to identify a region on SCARF1 for recognizing modified LDLs. The mutagenesis data show that the positively charged residues in the region are crucial for the interaction of SCARF1 with modified LDLs, which is confirmed by making chimeric molecules of SCARF1 and SCARF2. In addition, teichoic acids, a cell wall polymer expressed on the surface of gram-positive bacteria, are able to inhibit the interactions of modified LDLs with SCARF1, suggesting the ligand binding sites of SCARF1 might be shared for some of its scavenging targets. Overall, these results provide mechanistic insights into SCARF1 and its interactions with the ligands, which are important for understanding its physiological roles in homeostasis and the related diseases.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Jie Luo, Jeff Ranish
    Tools and Resources

    Dynamic conformational and structural changes in proteins and protein complexes play a central and ubiquitous role in the regulation of protein function, yet it is very challenging to study these changes, especially for large protein complexes, under physiological conditions. Here, we introduce a novel isobaric crosslinker, Qlinker, for studying conformational and structural changes in proteins and protein complexes using quantitative crosslinking mass spectrometry. Qlinkers are small and simple, amine-reactive molecules with an optimal extended distance of ~10 Å, which use MS2 reporter ions for relative quantification of Qlinker-modified peptides derived from different samples. We synthesized the 2-plex Q2linker and showed that the Q2linker can provide quantitative crosslinking data that pinpoints key conformational and structural changes in biosensors, binary and ternary complexes composed of the general transcription factors TBP, TFIIA, and TFIIB, and RNA polymerase II complexes.